- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03766516
Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HL (BRAVO)
A Multi-center and Non-interventional Registry of BrentuximabVedotinin Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma or Classical Hodgkin Lymphoma
In case of relapsed or refractory ALK-negative ALCL patients, high-dosage chemotherapy/ stem cell transplantation is a universal salvage option for patients with sensitivity to anti-cancer treatment and a relatively successful salvage rate can be expected.
Recently, there has been a report of successful stem cell transplantation with full response to BrentuximabVedotin induced before stem cell transplantation and BrentuximabVedotin's role as a bridge therapy before stem cell transplantation has also been suggested.
Hodgkin lymphoma is a type of curable blood cancer with unique tissues and clinical characteristics. Based on the 2008 WHO classification, Hodgkin lymphoma has two types-nodular lymphocyte predominant type and classical type-and the classical type is further classified into four types, nodular sclerosis, mixed cellularity, lymphocyte depletion and lymphocyte-rich type.
Recently, immune checkpoint inhibitor is reported as a very effective treatment for relapsed Hodgkin lymphoma and more active treatment such as stem cell transplantation is considered for younger patients.
Treatment with Brentuximabvedotin targeting CD30+ is also very effective for the treatment of relapsed Hodgkin lymphoma and considered a good option for patients who are not suitable for stem cell transplantation or aged patients.
It shows consistent response to anti-CD30 antibody treatment in relation to relapsed anaplastic large cell lymphoma or Hodgkin lymphoma. The effect of Brentuximabvedotin (BV) has been proven for relapsed or intractable ALCL targeting CD30 as an antibody-chemical adhesive in the recent phase-2 study.
As Korea currently lacks real-world evidence in relation to BV, this study was conducted to address BV's effect as salvage therapy for patients with relapsed/refractoryanaplastic large cell lymphoma or Hodgkin lymphoma. This study identified the clinical results for treatment patterns and patients using the collected data and derived critical evidence for treatment decisions.
Study Overview
Status
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Gangnam-Gu
-
Seoul, Gangnam-Gu, Korea, Republic of, 06351
- Samsung Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
- Any patient planning to administer BrentuximabVedotin to treat the target disease;
- Any patient administering BrentuximabVedotin to treat the target disease;
- Any patient tracing BrentuximabVedotin after treating the target disease; or
- Any patient administering another salvage option for cancer as the target disease has relapsed after terminating treatment using BrentuximabVedotin.
Description
Inclusion Criteria:
Any patient subject to one of the following at the start of treatment with BrentuximabVedotin:
- Any patient planning to administer BrentuximabVedotin to treat the target disease;
- Any patient administering BrentuximabVedotin to treat the target disease;
- Any patient tracing BrentuximabVedotin after treating the target disease; or
- Any patient administering another salvage option for cancer as the target disease has relapsed after terminating treatment using BrentuximabVedotin.
Exclusion Criteria:
- If conditions for target diseases are not met.
- If conditions for target patients are not met.
- If patients do not give written consent to participate in study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
---|
Cohort
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate
Time Frame: 3years
|
Rate of patients with complete response and partial response based on Lugano classification.
|
3years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response retention period
Time Frame: 3years
|
From 1st dose date of Brentuximab Vedotin to progression date.
|
3years
|
Overall survival period
Time Frame: 3years
|
Period from start of salvage therapy with Brentuximab Vedotin to end of study.
|
3years
|
Length of time until next treatment
Time Frame: 3years
|
Length of time from start of salvage therapy with Brentuximab Vedotin to next salvage option after progress of disease.
|
3years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-06-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed or Refractory Anaplastic Large Cell Lymphoma & Hodgkin Lymphoma
-
Millennium Pharmaceuticals, Inc.CompletedRelapsed or Refractory Hodgkin Lymphoma | Relapsed or Refractory Anaplastic Large-cell LymphomaUnited States, France, United Kingdom, Germany, Spain, Netherlands, Italy, Mexico
-
TakedaCompletedRelapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell LymphomaJapan
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownRelapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)China
-
Curis, Inc.The Leukemia and Lymphoma SocietyCompletedLymphoma | Refractory Lymphoma | Relapsed Lymphoma | Relapsed and/or Refractory Lymphoma | Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Double-hit Lymphoma (DHL) | Triple-hit Lymphoma... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Anaplastic Large Cell Lymphoma | Refractory Transformed Non-Hodgkin Lymphoma | Recurrent...United States
-
Hoffmann-La RocheCompletedRelapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell LymphomaUnited States, Spain, United Kingdom
-
Kite, A Gilead CompanyApproved for marketingRelapsed/Refractory Diffuse Large B Cell Lymphoma | Relapsed/Refractory Primary Mediastinal B Cell Lymphoma | Relapsed/Refractory Transformed Follicular Lymphoma | Relapsed/Refractory High-Grade B-Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides | Refractory Mycosis Fungoides | Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Refractory Anaplastic Large Cell Lymphoma | Recurrent Anaplastic Large Cell Lymphoma and other conditionsUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Not yet recruitingHodgkin Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Anaplastic Large Cell Lymphoma, ALK-negative | CD30-Positive Diffuse Large B-Cell Lymphoma | Anaplastic Large Cell Lymphoma, T Cell and Null Cell TypeUnited States
-
Millennium Pharmaceuticals, Inc.CompletedHodgkin Lymphoma | Anaplastic Large-cell LymphomaSpain, Belgium, Lithuania